NOTE 6 –OTHER RECEIVABLES,NET
Other receivables consisted of the following:
Other Receivable, Net - Schedule of Other Receivable
| | |
| | | |
| | |
| | |
December 31,
2025 | |
December 31,
2024 |
| Loan receivable(1) | |
$ | 14,355,283 | | |
$ | — | |
| Proceeds receivable from sale of subsidiary(2) | |
| 2,416,086 | | |
| — | |
| Other | |
| 559 | | |
| 94,074 | |
| Other
receivables, net | |
$ | 16,771,928 | | |
$ | 94,074 | |
| (1) | During the year ended December 31, 2025, the Company entered into
five borrowing arrangements with a third party for an aggregate principal amount of $14,160,101, bearing interest at 9% per annum. Certain
borrowings were guaranteed by individuals or entities or secured by certain assets. As of December 31, 2025, the aggregate accrued and
unpaid interest related to these borrowings was $195,182. |
To date, all of the above borrowings, including the
related accrued interest, had been fully repaid.
| (2) | There was $2,416,086 receivable from the sale of the Company’s subsidiary,
SYCI, which is due in 2026 from Shandong Rongyuan Pharmaceutical Co., Ltd. |
|